Latent infection of human bocavirus accompanied by flare of chronic cough, fatigue and episodes of viral replication in an immunocompetent adult patient, cologne, Germany by Windisch, Wolfram et al.
Case Report Latent infection of human bocavirus accompanied
by flare of chronic cough, fatigue and episodes of
viral replication in an immunocompetent adult
patient, Cologne, Germany
Wolfram Windisch,1 Monika Pieper,2 Inga Ziemele,3,4 Jürgen Rockstroh,5






Received 19 May 2016
Accepted 3 June 2016
1Department of Pneumology, Kliniken der Stadt Köln gGmbH, University of Witten/Herdecke,
Cologne, Germany
2Institut für Pathologie, Klinikum der Privaten Universit€at Witten/Herdecke mit Sitz in Köln,
Cologne, Germany
3Virology, University of Helsinki, Helsinki, Finland
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Introduction: The human bocavirus (HBoV) is a parvovirus and is associated with mild to life-
threatening acute or persisting respiratory infections, frequently accompanied by further
pathogens. So far, there is limited knowledge on the mechanisms of persistence, and no reports
on chronic infections or latency have been published so far.
Case presentation: An immunocompetent male patient suffers from a chronic HBoV1 infection,
i.e. viral DNA was detected in both serum and bronchoalveolar lavage (BAL) for >5 months
without co-infections and with respiratory symptoms resolved spontaneously while receiving
symptomatic treatment with montelukast and corticosteroids. Following the symptomatic
medication of a chronic infection with HBoV1 viraemia indicating active viral replication lasting
over 5 months, the patient cleared the viraemia and no further viral DNA was detectable in the
BAL. However, by fluorescence in situ hybridization analyses of mucosal biopsies, it was shown
that the virus genome still persisted in the absence of viral shedding but in a more compact
manner possibly representing a supercoiled episomal form of this otherwise linear single-
stranded DNA genome. This indicated the entry into a latency phase. Moreover, the cytokine
profile and the IP-10/TARC ratio, a marker for fibrotization, seem to have been altered by
HBoV1 replication. Although specific IgG antibodies were detectable during the whole
observation period, they showed an apparently insufficient neutralising activity.
Conclusion: On the one hand, these findings suggest that the symptomatic medication may
have led to clearance of the virus from blood and airways and, moreover, that the viral DNA
persists in the tissue as an altered episomal form favoured by lacking neutralising antibodies.
This appears to be important in order to reduce possible long-term effects such as lung fibrosis.
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Introduction
In the majority of clinical studies and single cases described
and observed so far, the human bocavirus (HBoV) type 1
HBoV1 was associated with mild to severe acute or persist-
ing respiratory infections and symptoms ranging from the
common cold to life-threatening pneumonia, mainly in
children but occasionally also in adults (Allander, 2008;
Garcia-Garcia et al., 2010).
Because no animal model is available so far due to the nar-
row host range of the virus, clinical cases, besides in vitro
Abbreviations: BAL, bronchoalveolar lavage; EIA, enzyme immunoassay;
FISH, fluorescence in situ hybridisation; HBoV, human bocavirus.
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studies in cell cultures, remain the major source of informa-
tion about the pathogenesis of this virus. One feature of
HBoV appears to be its ability to establish a latent stage or
even chronic infection (Byington et al., 2015; Kaur et al.,
2014; Schildgen et al., 2013; Windisch et al., 2013; Deng
et al., 2014; Manning et al., 2007; Schenk et al., 2011). There-
fore, the presented case is of major importance; as for the
first time, we describe an HBoV1-associated chronic respira-
tory infection in detail, provide evidence for clinical
improvement following symptomatic treatment, gain insight
into the molecular mechanisms of viral persistence and
immune evasion of the virus and provide evidence that the
chronic infection with HBoV can include flares of active
viral replication followed by symptom free latency.
Case report
The patient was a 29-year-old never-smoker Caucasian
male, who came to our out-patient clinic because of chronic
cough of so far unknown origin resistant to previous anti-
microbiotic treatment. When presenting first in May 2013,
the patient had symptoms of a persisting pharyngitis; from
this time point on, he suffered from a worsening of his
cough, which became chronic and persisted until January
2015. In addition, the patient described chronic fatigue that
prevents the patient from practising his profession as a
percussionist.
Bronchoscopy confirmed an acute tracheobronchitis in
February and June 2014. Thereby, macroscopically mucosal
lesions in the hypopharynx were observed in June 2014,
and a biopsy was taken in June 2014.
In February 2014, a mild alveolitis with increased lympho-
cyte subsets was confirmed in the BAL, and in both BALs
from February and June 2014, HBoV1-DNA (>105 copies
per millilitre) was detected by quantitative PCR (qPCR) in
both cases accompanied by a viraemia verified by detection
of viral DNA in corresponding serum samples indepen-
dently in Cologne and Helsinki. The copy numbers in the
sera were tested positive by qPCR in Cologne with 1.5103
(February) copies per millilitre and 1.8103 copies per
millilitre (June). Furthermore, a myocardiac biopsy was
taken in May 2014, which displayed a recently resolved
myocarditis.
Due to the long and ongoing clinical symptoms, the patient
was tested for an either primary or secondary immuno-
deficiency syndrome but neither an HIV infection nor any
other immunodeficiency was diagnosed, whereas a com-
bined type IIb hyperlipoproteinemia according to
Fredrickson and a leaky gut syndrome were diagnosed.
Investigations
Laboratory testing of the patient’s BAL included routine
screening for respiratory bacteria by conventional micro-
biological screening methods and by culturing. In addition,
the BALs were analysed for facultative and obligate
respiratory bacteria as well as viruses and fungi by the
Respifinder Smart 22 and Meningofinder Custom Assays
(i.e. the standard Meningofinder plus mumps and measles
probes, Pathofinder). The Respifinder and Meningofinder
assays were previously described as suitable and sensitive
tools by our group and others (Kaur et al., 2014; Hardt
et al., 2014; Wolffs et al., 2009; Dabisch-Ruthe et al., 2012;
Raymaekers et al., 2011). In detail, the patient’s BAL was
tested for influenza viruses, parainfluenza viruses 1–4, RSV,
HMPV, HBoV1, coronaviruses NL63, OC43, 229E and
HKU-1, adenoviruses, Mycoplasma pneumoniae, human
parechoviruses, rhinoviruses and enteroviruses, Legionella
pneumoniae, Chlamydia pneumoniae and Bordetella pertussis
by Respifinder; mumps, measles, herpes simplex 1, herpes
simplex 2, varicella zoster virus, Epstein Barr virus, cyto-
megalovirus, enterovirus and parechovirus by Meningo-
finder; Pneumocystis jirovecii by PCR (Schildgen et al.,
2014); and Aspergillus by ELISA (BioRad). Human herpesvi-
ruses 1–8 were also tested by qPCR as previously described
(Windisch et al., 2013). In addition, qPCR for quantifica-
tion of HBoV1 was performed as previously described using
the Qiagen QuantiTect Sybr Green Kit (Qiagen) using pri-
mers HBoV-Ku1 and HBoV-Ku2 followed by melting curve
analyses (Kaur et al., 2014; Kupfer et al., 2006). Mycobacte-
ria were tested by the MYCO-Direct 1.7 assay (Chipron).
Routine culturing, including culturing of anaerobic patho-
gens, was performed by a microbiology laboratory. The lab-
oratory results for viruses were further confirmed by the
University Hospital Bonn, where also an immunodeficiency
was excluded and normal immune cell counts and antibody
titres were confirmed.
So far, as there is limited information about the local
inflammation processes during an HBoV infection in vivo,
we decided to retrospectively test the two BAL fluids of
which aliquots were archived at  80

C for the presence of
cytokines, and we compared them to a BAL sampled in
January 2015, in which no HBoV1-DNA was detected any-
more. Therefore, the Abcam Cytokine Human Membrane
Antibody Array (80 Targets, ab133998) was used as previ-
ously described (Khalfaoui et al., 2016). The method detects
the cytokines ENA-78, GCSF, GM-CSF, GRO, GRO-alpha,
I-309, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12 p40/p70, IL-13, IL-15, IFN-gamma,
MCP-1, MCP-2, MCP-3, MCSF, MDC, MIG, MIP-1beta,
MIP-1delta, RANTES, SCF, SDF-1, TARC, TGF-beta1,
TNF-alpha, TNF-beta, EGF, IGF-I, Angiogenin, Oncostatin
M, Thrombopoietin, VEGF-A, PDGF-BB, Leptin, BDNF,
BLC, Ckß8-1, Eotaxin, Eotaxin-2, Eotaxin-3, FGF-4, FGF-
6, FGF-7, FGF-9, Flt-3 Ligand, Fractalkine, GCP-2, GDNF,
HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IL-16, IP-10,
LIF, LIGHT, MCP-4, MIF, MIP-3 alpha, NAP-2, NT-3, NT-
4, Osteopontin, Osteoprotegerin, PARC, PLGF, TGF-beta2,
TGF-beta3, TIMP-1 and TIMP-2, respectively.
Moreover, the hypopharyngeal biopsies were tested for
intracellular HBoV1-DNA by fluorescence in situ hybridiza-
tion (FISH) as previously described (Schildgen et al., 2013).
HBoV1-specific IgM and IgG antibodies were assayed in
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serum samples obtained in February and June 2014 by com-
petitive enzyme immunoassay (EIA) (Kantola et al., 2011).
The ODs measured in this ELISA were 1.589 for HBoV-1
IgG and 0.049 for HBoV-1 IgM in February, followed by
1.625 HBoV-1 IgG and 0.051 for HBoV-1 IgM in June,
both indicating a past immune reaction.
In both BAL samples from February and June 2014, all
tested pathogens that could have contributed to the clinical
symptoms were repeatedly excluded except HBoV1, whose
DNA was repeatedly detected by the Respifinder. The corre-
sponding sera were tested positive at the analytic borderline
of both the qPCR and the Respifinder assay performed in
Cologne and below the limit of detection in the qPCR per-
formed in Helsinki. Furthermore, the patient had medium
EIA absorbances (1.639 and 1.264) of HBoV1-specific IgG
antibodies with high avidity at both serum-collection points
but was negative for IgM, indicating past immunity.
So far, it was shown by Kapoor et al. and our group that the
HBoV-DNA can occur not only as a single-stranded DNA
molecule but also as a covalently closed circular DNA
(Kapoor et al., 2011; Lusebrink et al., 2011). Thereby, the
Right-End-Hairpin sequence represents the ‘tail’-sequence
while the Left-End-Hairpin represents the ‘head’-sequence
(Schildgen et al., 2012).
Besides the exclusive detection of HBoV-DNA in BAL and
serum in February and June 2014, viral episomes were
detected in the hypopharyngeal biopsy from June 2014
(Fig. 1a). These episomal structures were still present in the
second biopsy from January 2015 (Fig. 1b), although the
viraemia was cleared and the macroscopic inflammation
signs were no longer present at that moment; thus, in
January 2015, an objective improvement was clinically mea-
surable, although the virus still persisted in the mucosal
biopsies. Surprisingly, the HBoV FISH signals in the biopsy
from January had a different shape compared to the first
biopsy taken in June 2014. In June 2014, both the head
(green) and the tail (red) signals were adjacent to each other
but clearly divided, whereas in January 2015, the head and
tail signals show an overlay and appear as yellow signals
(Fig. 1b). Additionally, in some cases, single red signals
occur. The most likely structural explanation for the FISH
result is shown in Fig. 1c, which shows a scheme how the
red and green FISH signals are localized on the viral geno-
mic DNA in its putative forms (Fig. 1c).
Simultaneously with the disappearance of HBoV1-DNA
from BAL and serum, the majority of cytokines was down-
regulated in the BAL, such as RANTES, IL-3, IL-8, IL-10,
NAP-2, TIMP-1 and IP-10 (Fig. 2), while expressions of
RANTES, NAP-2, Eotaxin-2, TIMP-1, TNF-a and TNF-b
remain at the same level in the HBoV-negative compared to
the HBoV-positive serum. Moreover, the TARC/IP-10
increased during the HBoV infection in BAL (BALFeb14 :
0.28; BALJun14 : 0.34; BALJan15 : 0.85) as well as in the serum
(SERJun14 : 0.23; SERJan15 : 0.92), even when the viral DNA
disappeared in BAL and serum. Altogether, the cytokine
profiles observed in the stage of active replication followed
by vanishing of the virus resemble the cytokine profile for
chronic HBoV infections we previously described for a
patient cohort and infected CuFi-8 cell cultures (Khalfaoui
et al., 2016).
Diagnosis
The sole pathogen detected was the HBoV as described in
the case presentation.
Treatment
The patient was treated with montelukast and inhalative
budesonide for 6 months (from July 2014 to January 2015)
(Cai et al., 2012) and subsequently controlled in January
2015. In this control check, the macroscopic mucosal
lesions were not observed anymore, the patient displayed
no objective signs of an airway infection or inflammation of
respiratory epithelia, no pathogens were detected anymore
in the BAL and the patient’s serum tested negative for
HBoV1-DNA. This check-up was accompanied by sampling
of a follow-up hypopharyngeal-bronchial biopsy also show-
ing a recurrent finding.
Outcome and follow-up
At the end of the observation period of our hospital, the
patient appeared in increasing clinical condition before he
changed to another ambulant care.
Discussion
The present case is indeed important as it is a further con-
firmation of the hypothesis that HBoV is able to persist,
also in otherwise healthy patients; beyond this, the present
case report allows the conclusion that the virus not only can
enter a phase of latency but also can actively replicate, the
latter phase being accompanied by clinical symptoms. Here,
not only the virus was shed for an unusual long time in the
airways as already described by others (Martin et al., 2010;
Martin et al., 2015; Byington et al., 2015) but also the other-
wise short-lived viraemia lasted here over 5 months. Addi-
tionally, FISH staining revealed most likely an episomal
DNA structure in the respiratory mucosa, which could dis-
play a persisting form of the virus. The DNA occurred in
different shapes that may be compatible with the replication
stage. In June 2014, both the head signal and the tail signal
were adjacent to each other but clearly divided, indicating a
relaxed form of the circular DNA, maybe due to active viral
replication, whereas in January 2015, the signals show an
overlay and appear as yellow signals possibly indicating a
supercoiled form that is not actively replicating. Some single
red signals were also detected, which presumably represent
deletion forms of the viral genome. The FISH results are
consistent with the fact that, in January 2015, both the vir-
aemia and the BAL were cleared, while the previous investi-
gations were both tested positive for HBoV1-DNA.
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Although the detected viraemia was weak, there is a high like-
lihood that HBoV contributed to the clinical symptoms as the
virus was the single respiratory pathogen detected in the
patient. One can assume that HBoV1 replication took place
topical in the mucosal tissue where the viral DNA persisted,
what is supported by the fact that HBoV also replicates in foci
in cell culture (Dijkman et al., 2009). This would also explain
the low-level DNA amounts in asymptomatic blood donors,
in whom viral DNA could circulate in low amounts as long as
the virus persists and infected cells would be released to the
blood stream (Bonvicini et al., 2011).
Moreover, the patient displayed the persistent viraemia
despite the presence of specific antibodies. Although the
corticosteroids therapy could have transiently affected the
immune system, it must be taken into account that, it may
be possible that, HBoV1 does not induce neutralising anti-
bodies during the infection or triggers a so far unknown
immune-escape mechanism.
Besides, it is worth noting that the patient had a leaky gut
syndrome as well as a history of a myocarditis from which
he recovered because, in previous HBoV cases, we have
detected HBoV-DNA post-mortem also in the myocardic
tissue in patients that died from idiopathic lung fibrosis
(Windisch et al., 2013); thus, a causal link is possible and
requires further attention. Although no clinical symptoms
could be associated to HBoV detection, further reports of
HBoV-DNA detection in the heart tissue exist (Kuethe
et al., 2009). In concert with the fact that myocardial infec-
tions are frequently observed after common colds in
patients that were physically active during their common
cold, HBoV could be accused being a further player in this
clinical scenario. Consequently, as the leaky gut syndrome
could not be deduced to other factors such as diet, inherited
diseases or simultaneous infections, further studies should
investigate on the role of HBoV in this syndrome because it
could also be linked to the HBoV infection as HBoV is
widely detected in feces (Albuquerque et al., 2007; Lee et al.,
2007; Campe et al., 2008; Cheng et al., 2008; Yu et al., 2008;
Szomor et al., 2009).
As previously discussed, the Th2 response in the lung is
accompanied by increased expression levels of IL-4, IL-5,
IL-10 and IL-13 and is followed by increased levels of,
among others, TARC and RANTES (Berin et al., 2001;
Culley et al., 2006). Also in the present case, an increased
expression of RANTES and IL-10 besides IL-3, IL-8 and
IL-16 was observed in the acute replication period. In con-
trast, the comparison of sera and BALs reveals a delayed tis-
sue specific increase of Leptin, EGF, VEGF, TNF-a and
TNF-b, which are directly or indirectly involved in fibros-
ing processes. Moreover, the HBoV-specific cytokine profile
in the BAL is characterized by an imbalanced TARC/IP-10
ratio leading to the hypothesis that HBoV influences the
Predicted 








Fig. 1. This figure shows the FISH analysis of biopsies of respiratory mucosa sampled in June 2014 (a) during the phase of
active HBoV replication and in January 2015 (b) when blood and BAL were HBoV-DNA negative. Red signals show the HBoV
genome’s tail, and green signals show the genome’s head. The arrows indicate the signals. It is obvious that, in June 2014, the
signals were nearby each other, indicating an episomal form of the viral genome as described earlier by Kapoor et al. and our
group (Kapoor et al., 2011; Lusebrink et al., 2011) but even more condensed in January 2015 when no viral shedding was
observed anymore, thus maybe indicating a phase of latency. Panel (c) shows the putative DNA structures and the localization
of the FISH signals in the cccDNA/episomal DNA, the condensed/supercoiled form and the relaxed single-stranded genome.
The cccDNA thereby corresponds to panel A where active replication was observed, while the supercoiled form corresponds
to panel B where no active replication was observed.
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Th1/Th2 response within the lung. Furthermore, an imbal-
anced TARC/IP-10 ratio seems to be associated with fibrotic
lung diseases and it is worth to mention that the neutraliza-
tion of TARC leads to a reduction of fibrosis in the animal
(Keane, 2008; Belperio et al., 2004). Despite the growing
number of hints, more HBoV-positive follow-up cases have
to be analysed to confirm HBoV-specific immune response
modulation leading to chronic lung diseases.
However, the patient was successfully treated, and although
not having lost the virus from the mucosal biopsies, he
objectively recovered from the clinical symptoms and, as a
matter of evidence-based speculation, the virus replaced
active replication with a latency phase, as indicated by the
conformational change observed in the FISH analysis.
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